284 related articles for article (PubMed ID: 25258429)
1. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.
Caudill MM; Hunter AM; Cook IA; Leuchter AF
Clin EEG Neurosci; 2015 Oct; 46(4):277-84. PubMed ID: 25258429
[TBL] [Abstract][Full Text] [Related]
2. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
[TBL] [Abstract][Full Text] [Related]
4. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.
Leuchter AF; Cook IA; Marangell LB; Gilmer WS; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; McCracken JT; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):124-31. PubMed ID: 19712979
[TBL] [Abstract][Full Text] [Related]
7. The antidepressant efficacy of reboxetine in patients with severe depression.
Montgomery S; Ferguson JM; Schwartz GE
J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Langworth S; Bodlund O; Agren H
J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
10. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
11. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes.
Chuluunkhuu G; Nakahara N; Yanagisawa S; Kamae I
Kobe J Med Sci; 2008 Jul; 54(2):E147-58. PubMed ID: 18772616
[TBL] [Abstract][Full Text] [Related]
13. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
[TBL] [Abstract][Full Text] [Related]
14. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study.
Spronk D; Arns M; Barnett KJ; Cooper NJ; Gordon E
J Affect Disord; 2011 Jan; 128(1-2):41-8. PubMed ID: 20619899
[TBL] [Abstract][Full Text] [Related]
15. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
[TBL] [Abstract][Full Text] [Related]
16. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder.
Hunter AM; Cook IA; Leuchter AF
Psychiatr Clin North Am; 2007 Mar; 30(1):105-24. PubMed ID: 17362807
[TBL] [Abstract][Full Text] [Related]
17. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
Grassi L; Biancosino B; Marmai L; Righi R
J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
Burrows GD; Maguire KP; Norman TR
J Clin Psychiatry; 1998; 59 Suppl 14():4-7. PubMed ID: 9818623
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
Versiani M; Amin M; Chouinard G
J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
[TBL] [Abstract][Full Text] [Related]
20. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.
Krell HV; Leuchter AF; Morgan M; Cook IA; Abrams M
J Clin Psychiatry; 2004 Sep; 65(9):1174-9. PubMed ID: 15367043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
